96027-84-8

Usage

Uses

Used in Pharmaceutical Industry:
2-n-Butyl-4-[(2-Bromoethoxy)-3,5-diiodobenzoyl]benzofuran is used as a potential amiodarone metabolite in the pharmaceutical industry. Due to its significant structural similarity to thyroid hormone and its metabolites, the iodothyronamines, it may have implications in the development of treatments for thyroid-related conditions or in the study of thyroid hormone metabolism.
Used in Chemical Research:
As a light yellow solid with a unique structure, 2-n-Butyl-4-[(2-Bromoethoxy)-3,5-diiodobenzoyl]benzofuran can be utilized in chemical research for the investigation of its properties, reactivity, and potential interactions with other compounds. This may lead to the discovery of new applications or the enhancement of existing ones in various fields, including medicine, materials science, and environmental chemistry.

InChI:InChI=1/C21H19BrI2O3/c1-2-3-7-18-19(14-6-4-5-8-17(14)27-18)20(25)13-11-15(23)21(16(24)12-13)26-10-9-22/h4-6,8,11-12H,2-3,7,9-10H2,1H3

Upstream product

• 106-93-4 ethylene dibromide 
• 1951-26-4 2-n-butyl-3-(3',5'-diiodo-4'-hydroxybenzoyl)benzofuran 

Downstream Products

• 1096359-56-6 [4-(2-azido-ethoxy)-3,5-diiodo-phenyl]-(2-butyl-benzofuran-3-yl)-methanone 

Relevant academic research and scientific papers

Targeted SIRT3 agonist and application thereof in AML (acute myeloid leukemia) treatment drugs

The invention relates to a targeted SIRT3 agonist and application thereof in AML (acute myeloid leukemia) treatment drugs, which belong to the technical field of anti-hematologic tumor pharmacology. The technical problem which is solved by the invention is to provide a compound as the SIRT3 agonist. The compound includes the compound shown in the drawing or a pharmacologically acceptable salt thereof. The compound or the pharmacologically acceptable salt thereof disclosed by the invention can serve as the SIRT3 agonist, which has certain activity in resisting acute myeloid leukemia. The structural formula is shown in the description.

Trace amine-associated receptor 1 (TAAR1) is activated by amiodarone metabolites

Amiodarone (Cordarone, Wyeth-Ayerst Pharmaceuticals) is a clinically available drug used to treat a wide variety of cardiac arrhythmias. We report here the synthesis and characterization of a panel of potential amiodarone metabolites that have significant structural similarity to thyroid hormone and its metabolites the iodothyronamines. Several of these amiodarone derivatives act as specific agonists of the G protein-coupled receptor (GPCR) trace amine-associated receptor 1 (TAAR1). This result demonstrates a novel molecular target for amiodarone derivatives with potential clinical significance.

Pharmaceutical and veterinary compositions for the treatment of ischemic cardiac disorders

Pharmaceutical and veterinary compositions having as essential active ingredient at least one benzofuran derivative of the general formula: STR1 or a pharmaceutically acceptable acid addition salt thereof in which R represents an amino, monoethylamino or diethylamino radical and X1 and X2 represent hydrogen or iodine with the proviso that when R represents diethylamino X1 and X2 are different. These compositions are useful for the treatment of ischemic cardiac disorders.